Processed Red Meat Intake Linked to Increased Incidence of Blood Cancers
FRIDAY, March 24, 2023 -- Processed red meat intake is associated with an increased incidence of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) in a Japanese population, according to a study published online March 7 in Environmental... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 24, 2023 Category: Pharmaceuticals Source Type: news
Allogeneic Stem Cell Transplant Feasible for Leukemia in Elderly Patients
TUESDAY, Feb. 21, 2023 -- In elderly adults aged 60 years and older with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS), allogeneic hematopoietic stem cell transplant (HSCT) can be performed with acceptable overall survival and... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 21, 2023 Category: Pharmaceuticals Source Type: news
What Laboratory Tests Are Consistent with Transient Erythroblastopenia of Childhood?
Discussion
Transient erythroblastopenia of childhood (TEC) is an “…anemia with a hemoglobin level at least 2 [standard deviations] below normal and a low reticulocyte count in relationship to the anemia in the absence of evidence of alternative causes of anemia.” A bone marrow aspirate shows decreased or absent erythroid precursor cells if obtained. The etiology is not well understood but may have a stimulating cause such as a viral infection, an immune-related and/or genetic cause. Parvovirus causing bone marrow suppression has been implicated and there are cases of affected siblings.
TEC is most common ...
Source: PediatricEducation.org - February 6, 2023 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
Inflammatory VEXAS Syndrome May Not Be So Uncommon
(MedPage Today) -- VEXAS syndrome, a newly discovered inflammatory disease that has rheumatologic and hematologic features caused by mutations in the UBA1 gene, may be as common as Behcet's disease or myelodysplastic syndrome (MDS), researchers... (Source: MedPage Today Rheumatology)
Source: MedPage Today Rheumatology - January 24, 2023 Category: Rheumatology Source Type: news
2022 ICC Recategorization Facilitates Risk Stratification of Myelodysplastic Syndrome
THURSDAY, Jan. 19, 2023 -- Clinical characteristics, outcomes, and genetic features vary among different myelodysplastic syndrome (MDS) subtypes categorized using the 2022 International Consensus Classification (ICC), according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 19, 2023 Category: Pharmaceuticals Source Type: news
Five-Year Relative Survival 59.6 Percent in Lower-Risk Myelodysplastic Syndromes
WEDNESDAY, Nov. 23, 2022 -- About 40 percent of patients with lower-risk myelodysplastic syndromes (LR-MDS) die of MDS within five years, according to a study published online Nov. 6 in the British Journal of Haematology.
Krzysztof M ądry, M.D.,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 23, 2022 Category: Pharmaceuticals Source Type: news
Magrolimab-Azacitidine Shows Promise in Untreated High-Risk MDS
(MedPage Today) -- The investigational anti-CD47 monoclonal antibody magrolimab combined with azacitidine showed promising efficacy and was well tolerated in patients with untreated higher-risk myelodysplastic syndromes (MDS), according to a phase... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - September 29, 2022 Category: Hematology Source Type: news
Low-Dose Hypomethylating Agents in Lower-Risk MDS Yield Promising Outcomes
(MedPage Today) -- Low-dose hypomethylating agents (HMAs) was associated with favorable outcomes in previously untreated lower-risk myelodysplastic syndromes (MDS), according to a long-term analysis of a randomized phase II study.
With a follow... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - August 23, 2022 Category: Hematology Source Type: news
Camp Lejeune Veterans Win Justice
On Wednesday, Aug. 10, President Joe Biden signed the comprehensive Honoring Our PACT Act of 2022 into law, allowing military veterans and families harmed by contaminated water at Marine Corps Base Camp Lejeune to file lawsuits against the federal government.
The Camp Lejeune Justice Act of 2022, which focuses on four decades of water contamination, is just one part of the much broader PACT Act, which expands access to health care and disability benefits for veterans harmed by toxic exposures around the world.
Biden lauded the bipartisan support for the PACT Act at the signing.
“There are a lot of issues we can...
Source: Asbestos and Mesothelioma News - August 10, 2022 Category: Environmental Health Authors: Chris Elkins Tags: Veterans Source Type: news
New Options in Myelodysplastic Syndromes From ASCO 2022 New Options in Myelodysplastic Syndromes From ASCO 2022
Novel treatment options in lower- and higher-risk patients with myelodysplastic syndromes and a promising targeted therapy are among MDS highlights from ASCO 2022, as discussed by Dr Amy DeZern.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 28, 2022 Category: Consumer Health News Tags: None ReCAP Source Type: news
Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting
Long-term data at the European Hematology Association (EHA) 2022 congress expands understanding of the impact of Roche medicines in early-stage blood cancers with the goal of providing patients with robust and durable outcomes from their first treatmentUpdated data from phase III CLL14 study of Venclexta ®/Venclyxto® (venetoclax) plus Gazyva®/Gazyvaro® (obinutuzumab) showed more than 60% of previously untreated people with chronic lymphocytic leukaemia remained in remission five years after starting treatment[1]Final analysis of phase III GALLIUM study showed meaningful improvement in progression-free survival was main...
Source: Roche Investor Update - June 10, 2022 Category: Pharmaceuticals Source Type: news
Roche announces positive data from broad blood cancer portfolio at European Hematology Association Annual Meeting
Long-term data at the European Hematology Association (EHA) 2022 congress expands understanding of the impact of Roche medicines in early-stage blood cancers with the goal of providing patients with robust and durable outcomes from their first treatmentUpdated data from phase III CLL14 study of Venclexta ®/Venclyxto® (venetoclax) plus Gazyva®/Gazyvaro® (obinutuzumab) showed more than 60% of previously untreated people with chronic lymphocytic leukaemia remained in remission five years after starting treatment[1]Final analysis of phase III GALLIUM study showed meaningful improvement in progression-free survival was main...
Source: Roche Media News - June 10, 2022 Category: Pharmaceuticals Source Type: news
Eprenetapopt-Based Combo Impresses in TP53-Mutant AML/MDS
(MedPage Today) -- Eprenetapopt combined with azacitidine as maintenance therapy after hematopoietic cell transplantation (HCT) improved outcomes for patients with TP53-mutant acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), a... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 25, 2022 Category: Hematology Source Type: news
Blast Counts Not Enough to Distinguish MDS From AML, Experts Say Blast Counts Not Enough to Distinguish MDS From AML, Experts Say
Oncologists argue that in differentiating myelodysplastic syndrome from acute myeloid leukemia, more than just bone marrow blast cutoff should be considered.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 14, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
Aggressive Supportive Treatment for COVID-19 in Leukemia and MDS Aggressive Supportive Treatment for COVID-19 in Leukemia and MDS
New findings provide preliminary evidence to use aggressive supportive treatment of COVID-19 in patients with acute leukemias and myelodysplastic syndromes.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2021 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
